Publications (118) RICARDO CABALLERO COLLADO publications

filter_list

2025

  1. Cardiac electrical abnormalities in a mouse model of left ventricular non-compaction cardiomyopathy

    PLoS ONE, Vol. 20, Núm. 5 May

  2. Class III antiarrhythmic drugs

    Antiarrhythmic Drugs (Springer Nature), pp. 133-172

  3. Drug interactions of antiarrhythmic drugs

    Antiarrhythmic Drugs (Springer Nature), pp. 311-342

  4. Propionic Acidemia-Induced Proarrhythmic Electrophysiological Alterations in Human iPSC-Derived Cardiomyocytes

    Journal of Inherited Metabolic Disease, Vol. 48, Núm. 3

  5. Two concurrent mechanisms are responsible for the INa increase produced by dapagliflozin and empagliflozin in healthy and heart failure cardiomyocytes

    Biomedicine and Pharmacotherapy, Vol. 186

2024

  1. Coexistent HCN4 and GATA5 Rare Variants and Atrial Fibrillation in a Large Spanish Family

    Canadian Journal of Cardiology, Vol. 40, Núm. 7, pp. 1270-1280

  2. Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect

    Pharmacological Research, Vol. 200

  3. FABP4 Enhances Lipidic and Fibrotic Cardiac Structural and Ca2+ Dynamic Changes

    Circulation: Arrhythmia and Electrophysiology, Vol. 17, Núm. 9, pp. e012683

  4. News in cardiovascular pharmacotherapy from the ACC.24 Meeting

    European heart journal. Cardiovascular pharmacotherapy

  5. Reply to Benndorff and DiFrancesco: Reliable human HCN4 single-channel recordings using the cell-attached configuration in expression systems

    Proceedings of the National Academy of Sciences of the United States of America

  6. Variable Penetrance and Expressivity of a Rare Pore Loss-of-Function Mutation (p.L889V) of Nav1.5 Channels in Three Spanish Families

    International Journal of Molecular Sciences, Vol. 25, Núm. 9

2023

  1. A Cantú syndrome mutation produces dual effects on KATP channels by disrupting ankyrin B regulation

    The Journal of general physiology, Vol. 155, Núm. 1

  2. A gain-of-function HCN4 mutant in the HCN domain is responsible for inappropriate sinus tachycardia in a Spanish family

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120

  3. Sex and gender differences in the treatment of arterial hypertension

    Expert Review of Clinical Pharmacology, Vol. 16, Núm. 4, pp. 329-347

2022

  1. Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity

    Drug Safety, Vol. 45, Núm. 2, pp. 101-126

  2. Empagliflozin and Dapagliflozin Increase Na+ and Inward Rectifier K+ Current Densities in Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells (hiPSC-CMs)

    Cells, Vol. 11, Núm. 23

  3. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline

    Expert Opinion on Investigational Drugs, Vol. 31, Núm. 10, pp. 1027-1052

  4. Regulation of cardiac ion channels by transcription factors: Looking for new opportunities of druggable targets for the treatment of arrhythmias

    Biochemical Pharmacology, Vol. 204

  5. Sex-related differences in the pharmacological treatment of heart failure

    Pharmacology and Therapeutics, Vol. 229

  6. Tbx5 variants disrupt Nav1.5 function differently in patients diagnosed with Brugada or Long QT Syndrome

    Cardiovascular research, Vol. 118, Núm. 4, pp. 1046-1060